Healthcare Industry News: neurodiagnostic
News Release - May 7, 2007
Telzuit Medical Technologies: Telzuit and New Line Medical Sign Co-Marketing Agreement
New Line to distribute the STATPATCH system in Louisiana, Texas, Alabama, Mississippi, Tennessee and FloridaWe expect to begin shipping product to these markets in June
ORLANDO, FL--(Healthcare Sales & Marketing Network)--May 7, 2007 -- Telzuit Medical Technologies, Inc. (OTC BB:TZMT.OB ) announced that it has signed a co-marketing agreement with New Line Medical, Inc. to service New Line's customer base in the southeastern US beginning in June 2007. Telzuit is currently building inventory to service the anticipated volume that New Line will generate in its markets.
New Line Medical is a Louisiana corporation founded in 1992. New Line Medical is a distributor of point-of-care testing to physician offices with sales representatives spanning across 6 southern states. New Line Medical was one of the first distributors of Neurometrix, Inc.'s neurodiagnostic system.
Telzuit expects to announce more co-marketing and marketing arrangements over the next several weeks as it begins to create a national network of product distributors.
About Telzuit Medical Technologies, Inc.
Telzuit Medical Technologies, Inc. is dedicated to providing advanced mobile medicine to patients. The STATPATCH System is a full 12-lead, completely wireless Holter monitor. The STATPATCH System has been approved by the FDA under a 510-K filing. Telzuit also provides ultrasound medical imaging services to physicians in Central Florida through six mobile imaging units. Telzuit is based in Orlando. For more information about Telzuit, its business model and its products, please visit the Company's web site: http://www.telzuit.com
Forward-Looking Statements: Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties, including the effect of changing economic conditions, competition within the health products industry, customer acceptance of products, and other risks and uncertainties. Such forward-looking statements are not guarantees of performance, and Telzuit results could differ materially from those contained in such statements. These forward-looking statements speak only as of the date of this release, and Telzuit undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this release.
Source: Telzuit Medical Technologies
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
